S&P 500   3,207.92 (-0.58%)
DOW   26,719.61 (-0.56%)
QQQ   257.01 (-1.49%)
AAPL   384.20 (-1.71%)
MSFT   203.43 (-2.22%)
FB   238.06 (-0.92%)
GOOGL   1,498.38 (-1.22%)
AMZN   2,960.01 (-1.62%)
NVDA   402.30 (-1.66%)
CGC   17.83 (-1.76%)
BABA   242.63 (-2.64%)
MU   49.98 (-1.05%)
GE   7.13 (-0.14%)
TSLA   1,495.36 (-3.28%)
AMD   54.31 (-1.86%)
T   30.27 (+0.87%)
ACB   12.17 (-5.44%)
F   6.83 (+1.34%)
GILD   76.05 (-0.78%)
DIS   119.23 (-1.38%)
NFLX   519.50 (-0.72%)
BAC   24.01 (-2.40%)
BA   181.37 (-3.50%)
S&P 500   3,207.92 (-0.58%)
DOW   26,719.61 (-0.56%)
QQQ   257.01 (-1.49%)
AAPL   384.20 (-1.71%)
MSFT   203.43 (-2.22%)
FB   238.06 (-0.92%)
GOOGL   1,498.38 (-1.22%)
AMZN   2,960.01 (-1.62%)
NVDA   402.30 (-1.66%)
CGC   17.83 (-1.76%)
BABA   242.63 (-2.64%)
MU   49.98 (-1.05%)
GE   7.13 (-0.14%)
TSLA   1,495.36 (-3.28%)
AMD   54.31 (-1.86%)
T   30.27 (+0.87%)
ACB   12.17 (-5.44%)
F   6.83 (+1.34%)
GILD   76.05 (-0.78%)
DIS   119.23 (-1.38%)
NFLX   519.50 (-0.72%)
BAC   24.01 (-2.40%)
BA   181.37 (-3.50%)
S&P 500   3,207.92 (-0.58%)
DOW   26,719.61 (-0.56%)
QQQ   257.01 (-1.49%)
AAPL   384.20 (-1.71%)
MSFT   203.43 (-2.22%)
FB   238.06 (-0.92%)
GOOGL   1,498.38 (-1.22%)
AMZN   2,960.01 (-1.62%)
NVDA   402.30 (-1.66%)
CGC   17.83 (-1.76%)
BABA   242.63 (-2.64%)
MU   49.98 (-1.05%)
GE   7.13 (-0.14%)
TSLA   1,495.36 (-3.28%)
AMD   54.31 (-1.86%)
T   30.27 (+0.87%)
ACB   12.17 (-5.44%)
F   6.83 (+1.34%)
GILD   76.05 (-0.78%)
DIS   119.23 (-1.38%)
NFLX   519.50 (-0.72%)
BAC   24.01 (-2.40%)
BA   181.37 (-3.50%)
S&P 500   3,207.92 (-0.58%)
DOW   26,719.61 (-0.56%)
QQQ   257.01 (-1.49%)
AAPL   384.20 (-1.71%)
MSFT   203.43 (-2.22%)
FB   238.06 (-0.92%)
GOOGL   1,498.38 (-1.22%)
AMZN   2,960.01 (-1.62%)
NVDA   402.30 (-1.66%)
CGC   17.83 (-1.76%)
BABA   242.63 (-2.64%)
MU   49.98 (-1.05%)
GE   7.13 (-0.14%)
TSLA   1,495.36 (-3.28%)
AMD   54.31 (-1.86%)
T   30.27 (+0.87%)
ACB   12.17 (-5.44%)
F   6.83 (+1.34%)
GILD   76.05 (-0.78%)
DIS   119.23 (-1.38%)
NFLX   519.50 (-0.72%)
BAC   24.01 (-2.40%)
BA   181.37 (-3.50%)
Log in

NASDAQ:AERIAerie Pharmaceuticals Stock Price, Forecast & News

$13.66
-0.09 (-0.65 %)
(As of 07/16/2020 12:54 PM ET)
Add
Compare
Today's Range
$13.43
Now: $13.66
$13.99
50-Day Range
$12.97
MA: $14.54
$15.88
52-Week Range
$10.80
Now: $13.66
$26.34
Volume12,914 shs
Average Volume677,538 shs
Market Capitalization$634.78 million
P/E RatioN/A
Dividend YieldN/A
Beta1.06
Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, retinal diseases, and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. The company's advanced-stage product candidate is Roclatan, a once-daily eye drop to reduce IOP to treat patients with open-angle glaucoma and ocular hypertension. Aerie Pharmaceuticals, Inc. has a collaborative research, development, and licensing agreement with DSM. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Durham, North Carolina.
Read More
Aerie Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.4Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.61 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AERI
CUSIPN/A
Phone919-237-5300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$69.89 million
Book Value$3.60 per share

Profitability

Net Income$-199,580,000.00
Net Margins-252.92%

Miscellaneous

Employees353
Market Cap$634.78 million
Next Earnings Date8/5/2020 (Estimated)
OptionableOptionable

Receive AERI News and Ratings via Email

Sign-up to receive the latest news and ratings for AERI and its competitors with MarketBeat's FREE daily newsletter.

Aerie Pharmaceuticals (NASDAQ:AERI) Frequently Asked Questions

How has Aerie Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Aerie Pharmaceuticals' stock was trading at $14.55 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, AERI stock has decreased by 6.1% and is now trading at $13.66. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Aerie Pharmaceuticals?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aerie Pharmaceuticals in the last year. There are currently 2 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Aerie Pharmaceuticals.

When is Aerie Pharmaceuticals' next earnings date?

Aerie Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Aerie Pharmaceuticals.

How were Aerie Pharmaceuticals' earnings last quarter?

Aerie Pharmaceuticals Inc (NASDAQ:AERI) announced its earnings results on Wednesday, May, 6th. The company reported ($0.83) EPS for the quarter, missing the Zacks' consensus estimate of ($0.75) by $0.08. The business earned $20.34 million during the quarter, compared to analysts' expectations of $21.04 million. Aerie Pharmaceuticals had a negative return on equity of 95.74% and a negative net margin of 252.92%. View Aerie Pharmaceuticals' earnings history.

What price target have analysts set for AERI?

13 brokers have issued twelve-month target prices for Aerie Pharmaceuticals' stock. Their forecasts range from $17.00 to $53.00. On average, they expect Aerie Pharmaceuticals' share price to reach $33.85 in the next year. This suggests a possible upside of 147.8% from the stock's current price. View analysts' price targets for Aerie Pharmaceuticals.

What are Wall Street analysts saying about Aerie Pharmaceuticals stock?

Here are some recent quotes from research analysts about Aerie Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Aerie reported mixed results for the fourth quarter of 2019, as the loss came in wider than expected, while sales surpassed expectations. The volumes picked up in the last two months of 2019. Aerie has an impressive portfolio of two ophthalmology drugs — Rhopressa and Rocklatan. Rhopressa is a once-daily formulation for IOP in patients suffering from open-angle glaucoma and ocular hypertension, while Rocklatan is a once-daily, quadruple-action, fixed-dose combination of Rhopressa and Xalatan. Aerie also obtained the approval of Rhokiinsa in Europe. Approval in additional geographies will boost sales. Glaucoma is one of the largest segments in the ophthalmic market. While the targeted market represents potential, Aerie faces stiff competition from Lumigan and Vyzulta, among others. Shares have underperformed the industry in the past year." (2/24/2020)
  • 2. HC Wainwright analysts commented, "We recently lowered our 2019 revenue to just under $80M vs. prior guidance of $110-120M, and Aeri just lowered to $70-80M. While this looks far below consensus of $98M, we believe current expectation were more in the $85M range, thus guidance is not too far below that. Importantly, we believe the guidance is very achievable, and based only on what the company is already seeing internally in terms of orders, leading indicators and managed care progress, rather than on aggressive market-research based assumptions." (8/8/2019)

Has Aerie Pharmaceuticals been receiving favorable news coverage?

Media stories about AERI stock have trended positive this week, according to InfoTrie. InfoTrie scores the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Aerie Pharmaceuticals earned a coverage optimism score of 2.1 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the near term. View the latest news about Aerie Pharmaceuticals.

Are investors shorting Aerie Pharmaceuticals?

Aerie Pharmaceuticals saw a decrease in short interest in the month of June. As of June 30th, there was short interest totaling 9,220,000 shares, a decrease of 6.5% from the June 15th total of 9,860,000 shares. Based on an average daily trading volume, of 941,500 shares, the days-to-cover ratio is presently 9.8 days. Approximately 21.0% of the company's shares are sold short. View Aerie Pharmaceuticals' Current Options Chain.

Who are some of Aerie Pharmaceuticals' key competitors?

What other stocks do shareholders of Aerie Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aerie Pharmaceuticals investors own include Canopy Growth (CGC), NicOx (NICXF), Melinta Therapeutics (MLNT), NVIDIA (NVDA), Micron Technology (MU), BioMarin Pharmaceutical (BMRN), Gilead Sciences (GILD), Incyte (INCY), Puma Biotechnology (PBYI) and Alibaba Group (BABA).

Who are Aerie Pharmaceuticals' key executives?

Aerie Pharmaceuticals' management team includes the following people:
  • Dr. Vicente J. Anido Jr., CEO & Chairman (Age 66)
  • Mr. Thomas A. Mitro, Pres & COO (Age 61)
  • Dr. Casey C. Kopczynski, Co-Founder & Chief Scientific Officer (Age 58)
  • Mr. Richard James Rubino CPA, CFO, Sec. & Treasurer (Age 61)
  • Ms. Jessica Crespo CPA, Director of Accounting

What is Aerie Pharmaceuticals' stock symbol?

Aerie Pharmaceuticals trades on the NASDAQ under the ticker symbol "AERI."

Who are Aerie Pharmaceuticals' major shareholders?

Aerie Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Envestnet Asset Management Inc. (0.06%). Company insiders that own Aerie Pharmaceuticals stock include Casey C Kopczynski, Foresite Capital Fund Ii, LP, Foresite Capital Management Ii, Gerald D Cagle, Richard J Rubino, Thomas A Mitro and Vicente Anido Jr. View institutional ownership trends for Aerie Pharmaceuticals.

Which major investors are buying Aerie Pharmaceuticals stock?

AERI stock was acquired by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc.. Company insiders that have bought Aerie Pharmaceuticals stock in the last two years include Foresite Capital Fund Ii, LP, Foresite Capital Management Ii, Gerald D Cagle, Richard J Rubino, and Vicente Anido Jr. View insider buying and selling activity for Aerie Pharmaceuticals.

How do I buy shares of Aerie Pharmaceuticals?

Shares of AERI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Aerie Pharmaceuticals' stock price today?

One share of AERI stock can currently be purchased for approximately $13.66.

How big of a company is Aerie Pharmaceuticals?

Aerie Pharmaceuticals has a market capitalization of $634.78 million and generates $69.89 million in revenue each year. The company earns $-199,580,000.00 in net income (profit) each year or ($3.40) on an earnings per share basis. Aerie Pharmaceuticals employs 353 workers across the globe.

What is Aerie Pharmaceuticals' official website?

The official website for Aerie Pharmaceuticals is www.aeriepharma.com.

How can I contact Aerie Pharmaceuticals?

Aerie Pharmaceuticals' mailing address is 4301 Emperor Boulevard Suite 400, North Carolina NC, 27703. The company can be reached via phone at 919-237-5300 or via email at [email protected]

This page was last updated on 7/16/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.